{"pageContent": "Purpose of review: Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad consensus that men with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 disease, PSA >10, younger men and African-Americans are often excluded.", "metaData": {"source": "Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer\nhttps://pubmed.ncbi.nlm.nih.gov/10873066/"}}